India's Zydus Cadila to make Gilead's potential COVID-19 drug remdesivir
Published
Indian drugmaker Zydus Cadila said on Friday it signed a non-exclusive licensing pact with Gilead Sciences Inc to manufacture and market antiviral drug remdesivir, the first treatment to show improvement in COVID-19 trials.
Full Article